Humana (HUM)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$396.58+0.50%
Close 2026-07-08 · 1-day change
Reading HUM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HUM free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading HUM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HUM free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Humana's growth potential is supported by recent strong performance and strategic partnerships. The company beat earnings expectations with a non-GAAP EPS of 10.31. It trades at 25× P/E, below the peer median of 27×. This suggests the price reflects less growth than expected. A specific risk is management's unsteady performance, which is behind on commitments. Peer multiples imply a price about 24% below where it trades. This read is provisional.
Trailing returns as of 2026-07-08. HUM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 26 analysts currently covering HUM (as of Jul 2026).
Based on 14 Wall Street analysts offering 12-month price targets for HUM in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. Current price $396.58. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Acquisition interest indicates strong market position and growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-08. EPS is implied from price ÷ P/E. Not investment advice.
Current $396.58
The last 12 months of price, then the range of analyst 12-month targets from today’s $396.58.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Acquisition offer enhances growth potential and strategic positioning.
Illinois win enhances revenue potential and margin outlook.
New Medicaid program enhances growth potential and revenue.
Sale of Gentiva stake enhances capital allocation strategy.
Earnings beat indicates strong performance towards EPS guidance.